Australia markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
227.52-2.47 (-1.07%)
At close: 4:00PM EST

232.65 +5.13 (2.25%)
Pre-market: 4:11AM EST

Full screen
Trade prices are not sourced from all markets
Previous close229.99
Open229.99
Bid0.00 x 800
Ask0.00 x 800
Day's range226.90 - 230.50
52-week range177.05 - 276.69
Volume2,395,212
Avg. volume2,497,565
Market cap131.408B
Beta (5Y monthly)0.73
PE ratio (TTM)18.48
EPS (TTM)12.31
Earnings date28 Apr 2021 - 03 May 2021
Forward dividend & yield7.04 (3.06%)
Ex-dividend date11 Feb 2021
1y target est254.24
  • Amgen To Present At The Cowen 41st Annual Healthcare Conference
    PR Newswire

    Amgen To Present At The Cowen 41st Annual Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

  • Why Turning Point Is Turning Heads
    Motley Fool

    Why Turning Point Is Turning Heads

    This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?

  • Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
    PR Newswire

    Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

    Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at 1:00 p.m. ET. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with clinical trial investigators, will discuss the results of the tezepelumab Phase 3 NAVIGATOR study in patients with severe asthma.